SynthesisClinical and experimental medicine2019
The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis.
Synthesis in Clinical and experimental medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- LINC00657 exhibits oncogenic properties in prostate cancer and may serve as a prognostic biomarker in cancer.BMC cancer · 2025Pooled it
- Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.JAMA network open · 2024Pooled it
- Tislelizumab combined with gemcitabine plus cisplatin for muscle-invasive upper tract urothelial carcinoma: A retrospective single-center cohort analysis.The Journal of international medical research · 2026Article
- Exploring the Role Of CD155 in Urothelial Carcinoma of the Urinary Bladder: An Immunohistochemical Study & Its Correlation With PD-L1.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- ST8SIA6-AS1 serves as a prognostic biomarker in cancer and exhibits oncogenic properties in prostate cancer.Frontiers in genetics · 2025Article
- Article
- PD-L1 expression and microsatellite instability (MSI) in cancer of unknown primary site.International journal of clinical oncology · 2024Article
- Article
- Integrating the PD-L1 Prognostic Biomarker in Non-Muscle Invasive Bladder Cancer in Clinical Practice-A Comprehensive Review on State-of-the-Art Advances and Critical Issues.Journal of clinical medicine · 2024Review
- The Relationship Between PD-1(rs2227981) and PD-L1(rs2890658) Polymorphisms and Urothelial Cell Carcinoma.Cureus · 2023Article
- Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study.Frontiers in oncology · 2023Article
- Cytoplasmic expression of G protein-coupled estrogen receptor 1 correlates with poor postoperative prognosis in non-small cell lung cancer.Journal of thoracic disease · 2022Article
- Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab.Cold Spring Harbor molecular case studies · 2022Article
- Review
- Role of GPER1 in the Mechanism of EGFR-TKIs Resistance in Lung Adenocarcinoma.Frontiers in oncology · 2022Article
- Prognostic value of PD-L1 combined positive score in patients with upper tract urothelial carcinoma.Cancer immunology, immunotherapy : CII · 2021Article
- Programmed cell death-ligand 1 assessment in urothelial carcinoma: prospect and limitation.Journal of pathology and translational medicine · 2021Review
- Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report.SAGE open medical case reports · 2020Article
- Involvement of FGFR4 Gene Variants on the Clinicopathological Severity in Urothelial Cell Carcinoma.International journal of environmental research and public health · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
The prognostic value of programed death-ligand 1 (PD-L1) in urothelial carcinoma (UC) has been assessed in previous studies, while the results remain controversial and heterogeneous. Therefore, we performed this meta-analysis to explore the prognostic effect of PD-L1 in patients with UC. PubMed, Embase and Web of Science were searched to identify the studies. Hazard ratios (HR) with 95% confidence interval (95% CI) and clinicopathological factors were extracted from included studies. A total of 1819 patients with UC from 11 published studies were incorporated. The results of meta-analysis showed that positive PD-L1 expression was significantly associated with poorer overall survival (OS) (HR 1.59, 95% CI 1.05-2.40) and disease-free survival (DFS) (HR 1.83, 95% CI 1.03-3.25), but not recurrence-free survival. Moreover, in the subgroup analysis, significant associations between PD-L1 expression and OS or DFS were found in bladder UC, the cutoff value of positive expression of PD-L1 ≥ 5% and the expression of PD-L1 on the tumor cell membrane. Interestingly, positive PD-L1 expression was correlated with poorer pathological T stage (OR 2.03, 95% CI 1.46-2.82). Our meta-analysis implies that PD-L1 might be a valuable biomarker of poor prognosis for UC, especially bladder UC, although further large-scale and well-designed studies are warranted to verify the prognostic value of PD-L1 for UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.